Heidelberg Pharma AG (XTRA: HPHA)
Health Care · Biotechnology · DE
€2.23
-5.11% today · -28.8% 1Y
Heidelberg Pharma AG (XTRA: HPHA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $116.82M and employs 41 people.
Over the last twelve months the share price has lost 28.8%, trading between 2.21 and 3.34.
Tweenvest scores Heidelberg Pharma AG across four factors: quality 31/100, value 43/100, growth 0/100. Its strongest factor is value.
HPHA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $116.82M
- Revenue (TTM)
- $8.70M
- P/E
- —
- EPS
- -0.71
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- €3.34
- 52-week low
- €2.21
- Avg volume (3M)
- —
- Shares outstanding
- 46.78M
- Employees
- 41
- Next earnings
- —
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
- ISIN
- DE000A11QVV0
- Founded
- 1997
- Listed since
- Nov 13, 2006
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Foghorn Therapeutics Inc.NasdaqGM: FHTX | $118.77M | $1.90 | -5.00% |
| Cibus, Inc.NasdaqCM: CBUS | $118.46M | $1.42 | -8.71% |
| Nykode Therapeutics ASOB: NYKD | $117.42M | Nkr3.20 | -6.98% |
| Oncopeptides AB (publ)OM: ONCO | $117.17M | Skr2.96 | +40.74% |
| Coya Therapeutics, Inc.NasdaqCM: COYA | $116.12M | $4.60 | -7.07% |
| enGene Therapeutics Inc.NasdaqCM: ENGN | $115.94M | $1.63 | -6.07% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| PMV Pharmaceuticals, Inc.NasdaqGS: PMVP | $114.78M | $1.39 | -8.55% |
Figures last refreshed Oct 11, 2026.